2 completed, 1 unknown, 1 withdrawn. 4 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 2, Unknown 1, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow Dermatofibrosarcoma: new trials by email Literature Review of Dermatofibrosarcoma trials Research Report on Dermatofibrosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma Brigimadlin, Ezabenlimab, Gemcitabine - Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS) | Phase 3 | Withdrawn | Boehringer Ingelheim | 2024-06-27 | 2024-07-17 | |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide - Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 140 | 2014-08-12 | 2026-06-17 |
| Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma doxorubicin hydrochloride, clinical observation, therapeutic conventional surgery - Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma | Phase 3 | Completed | Children's Oncology Group | 588 | 2007-02-05 | 2022-04-28 |
| Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma doxorubicin hydrochloride, ifosfamide, adjuvant therapy - Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma | Phase 3 | Unknown | European Paediatric Soft Tissue Sarcoma Study Group | 250 | 2006-03-01 | 2013-08-12 |
Fibrosarcoma (3) · Histiocytoma, Malignant Fibrous (3) · Liposarcoma (3) · Sarcoma (3) · Chondrosarcoma, Extraskeletal Myxoid (2) · Hemangiopericytoma, Malignant (2) · Hemangiosarcoma (2) · Leiomyosarcoma (2) · Neurofibrosarcoma (2) · Sarcoma, Alveolar Soft Part (2) · Sarcoma, Synovial (2) · Chondrosarcoma (1) · Chondrosarcoma, Mesenchymal (1) · Granuloma, Plasma Cell (1)
Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms, Connective Tissue (4) · Neoplasms, Connective and Soft Tissue (4) · Neoplasms, Fibrous Tissue (4) · Histiocytoma (3) · Neoplasms, Adipose Tissue (3) · Neoplasms, Muscle Tissue (2) · Neoplasms, Nerve Tissue (2) · Neoplasms, Vascular Tissue (2) · Nervous System Diseases (2) · Nervous System Neoplasms (2) · Neurofibroma (2) · Neuromuscular Diseases (2) · Peripheral Nervous System Diseases (2)
Doxorubicin (3) · Ifosfamide (3) · Radiotherapy (2) · Chemotherapy, Adjuvant (1) · Docetaxel (1) · Gemcitabine (1) · Neoadjuvant Therapy (1) · Observation (1) · Radiation (1) · Radiotherapy, Conformal (1) · Watchful Waiting (1) · brigimadlin (1) · indolepropanol phosphate (1) · pazopanib (1)
Boehringer Ingelheim (1) · Children's Oncology Group (1) · European Paediatric Soft Tissue Sarcoma Study Group (1) · National Cancer Institute (NCI) (1)
Canada (2) · Puerto Rico (2) · United States (2) · Australia (1) · Austria (1) · Belgium (1) · Denmark (1) · France (1) · Ireland (1) · New Zealand (1) · Spain (1) · Sweden (1) · Switzerland (1) · United Kingdom (1)
Aaron R Weiss (1) · Andrea Ferrari, MD (1) · Bernadette Brennan, MD (1) · Joern Treuner, MD (1) · Max Van Noesel, MD, PhD (1) · Modesto Carli, MD (1) · Sheri Spunt, MD (1)
PMID 28391003, PMID 30954717, PMID 31786124, PMID 32702309, PMID 32827353, PMID 33548339, PMID 34515544, PMID 34623899, PMID 36566574, PMID 37523624, PMID 38757485, PMID 41386267
U10CA098543 (2), U10CA180830 (1), U10CA180886 (1)